Is Group G Strep Dangerous? Symptoms and Potential Risks

Group G Streptococcus (GGS) sits in an uncomfortable gray zone: it can live harmlessly in your throat or on your skin, yet in certain circumstances it causes infections serious enough to be fatal. The bacterium most often responsible, Streptococcus dysgalactiae subspecies equisimilis (SDSE), is increasingly recognized as an emerging human pathogen whose clinical significance has been underappreciated for decades.¹ For most healthy people, a GGS encounter means a sore throat or a skin infection that clears up with antibiotics. But in older adults and people with chronic illnesses, the same organism can invade the bloodstream and reach the heart, joints, and brain.

What Group G Strep Typically Looks Like

The most common infections caused by GGS are throat infections (pharyngitis) and skin and soft-tissue infections such as cellulitis and wound infections.² A GGS pharyngitis feels much like a strep throat caused by Group A Strep: sore throat, fever, swollen tonsils, sometimes swollen lymph nodes in the neck. Clinically, these episodes are usually mild, respond well to penicillin, and resolve without complications in otherwise healthy individuals.

Skin infections tend to show up as spreading redness, warmth, and pain around a wound or break in the skin. Cellulitis and erysipelas from GGS look essentially the same as the Group A versions, and they’re treated the same way. Because rapid strep tests used in most clinics are designed to detect Group A, a GGS throat infection can easily go undiagnosed or be labeled “viral” if the rapid test comes back negative and no culture is sent. That’s worth knowing if your symptoms strongly suggest strep but the quick office test says otherwise.

When GGS Becomes Dangerous

The real concern with GGS isn’t the sore throat. It’s what happens when the bacterium crosses into the bloodstream, a situation called invasive disease. GGS can invade the blood and spread to deep tissue sites throughout the body, including the heart’s inner lining.² Life-threatening invasive infections, including streptococcal toxic shock syndrome, occur most often in patients who already have serious underlying conditions.

Streptococcal toxic shock syndrome (STSS) caused by GGS is documented but still considered uncommon. It involves dangerously low blood pressure and failure of multiple organ systems. While STSS is usually associated with Group A Strep, case reports and small series have established that GGS can trigger it as well.³ The diagnostic criteria for STSS are the same regardless of the streptococcal group: low blood pressure, evidence of at least two failing organ systems, and the presence of a streptococcal species in cultures.⁴ Recognizing that GGS can cause this syndrome matters because clinicians who don’t consider it may not act quickly enough when cultures identify a Group G organism.

GGS and Heart Infections

One of the more serious complications of GGS bacteremia is infective endocarditis, an infection of the heart valves. GGS accounts for roughly 3.5% of all patients with bacteremia, and among those patients, the rate of endocarditis varies widely across studies, from as low as 1% up to 25–50% in some series. Compared to endocarditis caused by other streptococcal species, GGS endocarditis tends to follow a more aggressive course.⁵

A Canadian study looking at Group C and G streptococcal bacteremia found that suspected or confirmed endocarditis occurred in about 6% of all patients and 18% of those who received an echocardiogram. Among patients with confirmed endocarditis, the infection spread to other sites in nearly two-thirds of cases, most commonly to the lungs, skin, bones and joints, and the central nervous system. About half of the endocarditis patients developed toxic shock syndrome, and overall mortality was 17%.⁶

One particularly striking case report described a 53-year-old man with a prosthetic heart valve who developed GGS bacteremia that led to endocarditis, infection inside both eyes, and bacterial meningitis simultaneously. His initial echocardiogram missed the valve infection entirely; it took a nuclear imaging scan to confirm it. He required eight weeks of intravenous antibiotics and eye surgery.⁷ Cases like this underscore why GGS bacteremia isn’t something to shrug off. When blood cultures grow GGS, clinicians need to actively look for endocarditis and other secondary sites of infection, because missing them has real consequences.

Joints and Bones

GGS has a particular affinity for joints and bone tissue in some patients. Septic arthritis, where the bacterium infects a joint directly, can cause acute swelling, pain, and fever. Published cases include patients who developed migrating septic arthritis, meaning the infection jumped between multiple joints, along with widespread muscle inflammation.⁸ Osteomyelitis, an infection of the bone itself, has also been reported, though fewer cases appear in the literature.⁹

One case involved a 55-year-old woman with breast cancer who developed a swollen, infected knee from GGS. The pus drained from the joint grew Group G Streptococcus.¹⁰ A pediatric case involved a 14-year-old girl with Gaucher disease who developed GGS bacteremia and vertebral osteomyelitis, presenting with severe back pain.¹¹ What ties these cases together is that virtually every patient who develops deep bone or joint infection from GGS has some underlying condition that weakens the immune system or damages tissue. In healthy people without predisposing factors, these complications are extremely rare.

Who Is Most at Risk

The pattern in the clinical literature is consistent: invasive GGS disease overwhelmingly affects people with weakened defenses. The conditions most frequently mentioned include diabetes, cancer, liver disease, heart failure, kidney disease, and immunosuppressive therapy. Age is a major factor as well, with incidence rising sharply in people over 60.

Diabetes deserves special mention because its relationship with GGS has been studied directly. In a large study comparing people with diabetes to population controls, diabetes carried roughly a 2.6-fold increased risk of GGS bacteremia specifically. Among people with type 1 diabetes, the risk was dramatically higher. The risk also climbed with the duration of diabetes and worsening blood sugar control: those with poorly controlled diabetes had about 3.6 times the risk compared to the general population.¹² Diabetes damages small blood vessels, impairs immune-cell function, and makes skin more susceptible to breakdown, all of which give bacteria an entry route and a weakened host response to fight them.

Skin breakdown from any cause is a common thread. People with chronic leg ulcers, lymphedema, surgical wounds, or conditions that compromise the skin barrier are at heightened risk, because the skin is one of the primary places GGS colonizes. Once the skin is broken, bacteria that were sitting harmlessly on the surface can reach deeper tissues and the bloodstream.

Incidence Is Rising

GGS infections are not just underappreciated; they’re becoming more common. A study spanning more than a decade in Japan found that the incidence of invasive GGS disease nearly doubled between the first and last five-year periods, peaking at about 3.3 per 100,000 inhabitants. During the most recent study year, invasive GGS surpassed both Group A and Group B streptococcal infections in frequency.¹³

Several factors probably contribute to the trend. Aging populations in developed countries mean more people living with the chronic conditions that predispose to invasive GGS disease. Better laboratory techniques have also improved detection: historically, many Group G isolates were either lumped together with other streptococci or misidentified. Modern identification tools are now resolving that problem, which means part of the observed increase reflects better recognition rather than a true surge in infections. Still, the upward trend is consistent enough across multiple countries that clinicians and public health authorities are paying closer attention than they were a generation ago.

How GGS Compares to Group A Strep

Much of the confusion around Group G Strep comes from its close resemblance to Group A Strep (GAS), the classic “strep throat” pathogen. The two organisms are microbiologically similar, and SDSE shares several virulence traits with Streptococcus pyogenes.² Research has shown that human-associated GGS strains carry genes related to Group A’s M protein, a key surface molecule that helps the bacterium evade the immune system. Animal-associated GGS strains, by contrast, lack these genes.¹⁴ This genetic overlap helps explain why human GGS infections can look so similar to GAS infections clinically.

One important difference, however, concerns post-infectious complications. GAS is well known for triggering rheumatic fever and kidney inflammation (glomerulonephritis) as immune-mediated aftereffects. These complications are classic to Group A Streptococcus and arise because the immune response to the infection damages the body’s own tissues. While isolated case reports occasionally mention glomerulonephritis after GGS infection, these post-infectious syndromes are not an established feature of GGS disease the way they are for GAS. This is meaningful because it changes the follow-up calculus: after a confirmed GAS pharyngitis, clinicians worry about rheumatic fever and may extend antibiotic therapy accordingly. After a GGS pharyngitis, that specific concern is much less pressing.

Treatment and the Resistance Question

The good news for treatment is straightforward: GGS remains universally susceptible to penicillin. For straightforward throat and skin infections, standard courses of penicillin or amoxicillin work reliably. For invasive disease and endocarditis, high-dose intravenous penicillin or ampicillin, often combined with other antibiotics, is the standard approach. The 53-year-old endocarditis patient discussed earlier, for example, received ampicillin intravenously for eight weeks.⁷

The worry is what’s happening with second-line antibiotics. Studies of SDSE isolates have found alarming rates of resistance to macrolides (like azithromycin and erythromycin), tetracyclines, and fluoroquinolones. Most erythromycin-resistant strains are also resistant to clindamycin.¹⁵ This matters for anyone with a penicillin allergy. If you can’t take penicillin, the usual alternatives for strep infections are macrolides and clindamycin, and GGS is increasingly resistant to both. Patients with true penicillin allergies and GGS infections may need allergy testing to see if penicillin can safely be used, or their clinicians may need to turn to less common antibiotic classes.

The Diagnostic Challenge

Identifying GGS accurately is trickier than it sounds. In routine clinical labs, streptococci are typically classified by their Lancefield group antigen (A, B, C, G, etc.), and that classification system works well enough for Group A and Group B. But for GGS, subspecies-level identification matters, because not all Group G streptococci are equally pathogenic, and treatment decisions sometimes depend on knowing you’re dealing with SDSE rather than another species that happens to carry the Group G antigen.

Modern identification technology using mass spectrometry has improved things considerably, but there are still gaps. One study found that only about 62% of SDSE isolates were correctly identified to the species level using the default mass spectrometry database. After the researchers refined the database by removing a few misleading reference entries, the accuracy jumped to 94%.¹⁶ The practical implication is that some clinical labs may still be reporting GGS isolates with less precision than ideal, potentially confusing SDSE with Streptococcus pyogenes (Group A) or Streptococcus canis (an animal-associated species). Misidentification in either direction could affect treatment decisions and epidemiological tracking.

Genomic analysis has also revealed substantial genetic diversity within SDSE. Studies using techniques like pulsed-field electrophoresis and gene-by-gene profiling show significant variation among strains, particularly in virulence-related genes.¹ This genetic heterogeneity likely explains some of the clinical variability: why some GGS strains cause nothing worse than a sore throat while others disseminate aggressively. As genomic tools become cheaper and more widely available, researchers hope to identify which strain features predict severe disease, which would allow for earlier escalation of treatment when it matters most.

GGS in Children

Invasive GGS disease is overwhelmingly a problem of older adults, which is why most clinical guidance focuses on that population. But it does occur in children, particularly those with underlying health conditions. The pediatric case of vertebral osteomyelitis mentioned earlier involved a teenager with Gaucher disease, a genetic condition that alters immune cell function.¹¹ Published pediatric cases are rare enough that each one tends to become a case report, which itself tells you something about how unusual serious GGS disease is in young, otherwise healthy people.

Where GGS does show up more commonly in children is in the throat. Some studies have found GGS in throat cultures of children with pharyngitis whose rapid strep tests (targeting Group A) were negative. Whether GGS is actually causing the sore throat in these cases, or simply living harmlessly in the throat while a virus causes the symptoms, remains debated. Many people carry GGS in their throat without any symptoms at all, so a positive culture doesn’t automatically mean GGS is the culprit. For parents, the practical takeaway is that if your child has a convincing strep-like illness but the rapid test is negative, asking for a throat culture can sometimes reveal GGS or other non-Group A streptococci as the cause.

Asymptomatic Carriage and Practical Perspective

It bears emphasizing that many encounters with GGS are entirely silent. The bacterium colonizes the throat, skin, and gastrointestinal and urogenital tracts of healthy individuals without causing any disease. Carriage rates vary by population and body site, but the key point is that simply having GGS on your body does not mean you are sick or at risk. The shift from harmless colonizer to invasive pathogen typically requires some combination of compromised host defenses, skin or mucosal barrier breakdown, and possibly a particularly virulent strain.

For healthy adults who develop a GGS throat or skin infection, the experience will likely be unremarkable: a course of antibiotics, symptom resolution, and no lasting effects. The people who need to take GGS seriously are those managing diabetes (especially poorly controlled diabetes), cancer patients on chemotherapy, people with heart valve abnormalities or prosthetic valves, those on immunosuppressive medications, and anyone with chronic wounds or skin breakdown. If you fall into one of those groups and develop signs of an infection, mentioning your risk factors to your healthcare provider can prompt the kind of thorough workup that catches complications early. GGS is not a pathogen that most healthy people need to lose sleep over, but it deserves more respect than it has historically received from the medical community, particularly given its rising incidence and its capacity to cause serious disease when conditions align.